Avalon GloboCare receives CNIPA patent allowance for CAR-T/NK cell therapy technology

Avalon GloboCare Corp.

Notice of Allowance from China National Intellectual Property Administration for patent AVAR1901CN, co-developed with Arbele Limited.
Patent covers bispecific anti-CD19xCD22 CAR design and localized cytokine induction to enhance CAR cell cytotoxicity, survival, and proliferation.
Technology aims to improve expansion, manufacturing, and efficacy of CAR-T and CAR-NK cells for cancer treatment.
Extends Avalon's global IP footprint to China, supplementing existing U.S. and PCT protections.
CEO David Jin highlights potential for practical, cost-effective point-of-care cancer solutions.

item 7.01 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001213900-25-014619
form_type: 8-K
ticker: ALBT
cik: 0001630212
company_name: Avalon GloboCare Corp.
filed_at: 2025-02-18T23:59:59+00:00
discovered_at: 2026-05-14T18:03:04.241373+00:00
generated_at: 2026-05-26T16:35:05.879352+00:00
sec_items: ["7.01", "9.01"]
event_type: other_material
sentiment: positive
materiality_score: 0.6
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001213900-25-014619
json_url: https://secwatch.observer/filing/0001213900-25-014619.json
markdown_url: https://secwatch.observer/filing/0001213900-25-014619.md
text_url: https://secwatch.observer/filing/0001213900-25-014619.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1630212/000121390025014619/0001213900-25-014619-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1630212/000121390025014619/ea0231383-8k_avalon.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0001213900-25-014619

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.